Healthcare provider profile · identity verified

Stephen Neabore, MD

Internal Medicine · WASHINGTON, DC · NPI 1629336821

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	338	87
Levothyroxine Sodium	Levothyroxine Sodium	228	54
Losartan Potassium	Losartan Potassium	210	57
Amlodipine Besylate	Amlodipine Besylate	203	57
Lisinopril	Lisinopril	150	39
Tamsulosin Hcl	Tamsulosin Hcl	144	37
Rosuvastatin Calcium	Rosuvastatin Calcium	138	43
Omeprazole	Omeprazole	131	40
Metformin Hcl	Metformin Hcl	92	22
Potassium Chloride	Potassium Chloride	90	22
Metoprolol Succinate	Metoprolol Succinate	84	26
Furosemide	Furosemide	79	24
Pravastatin Sodium	Pravastatin Sodium	79	20
Allopurinol	Allopurinol	75	20
Albuterol Sulfate Hfa	Albuterol Sulfate	72	21
Gabapentin	Gabapentin	69	18
Hydrochlorothiazide	Hydrochlorothiazide	69	22
Pantoprazole Sodium	Pantoprazole Sodium	68	17
Sertraline Hcl	Sertraline Hcl	65	18
Simvastatin	Simvastatin	64	18
Eliquis	Apixaban	60	19
Spironolactone	Spironolactone	60	15
Trazodone Hcl	Trazodone Hcl	58	18
Synthroid	Levothyroxine Sodium	47	15
Clopidogrel	Clopidogrel Bisulfate	46	15
Escitalopram Oxalate	Escitalopram Oxalate	44	12
Metformin Hcl Er	Metformin Hcl	43	13
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	37	37
Jardiance	Empagliflozin	36	suppressed
Bupropion Xl	Bupropion Hcl	33	suppressed
Carvedilol	Carvedilol	33	suppressed
Montelukast Sodium	Montelukast Sodium	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	31	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Spiriva Respimat	Tiotropium Bromide	28	suppressed
Chlorthalidone	Chlorthalidone	27	suppressed
Pregabalin	Pregabalin	27	suppressed
Propranolol Hcl Er	Propranolol Hcl	26	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	26	23
Finasteride	Finasteride	25	suppressed
Atenolol	Atenolol	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Lansoprazole	Lansoprazole	22	suppressed
Ozempic	Semaglutide	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Celecoxib	Celecoxib	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Buprenorphine	Buprenorphine	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Dutasteride	Dutasteride	16	suppressed
Invokana	Canagliflozin	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Linzess	Linaclotide	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Bethanechol Chloride	Bethanechol Chloride	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Alendronate Sodium	Alendronate Sodium	12	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	12	12
Enalapril Maleate	Enalapril Maleate	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error